Pharmaceutical News

RSS

Orthopedic surgery patients can recover just as well without using opioid-based painkillers

Patients can recover from orthopedic surgery just as well without using opioid-based painkillers, says a McMaster University and Hamilton Health Sciences (HHS) study published by the Journal of the American Medical Association.

5 Oct 2022

Viagra and Cialis may not be suitable candidates for treating dementia, NIH DREAM study shows

Results from the National Institutes of Health's Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study show that sildenafil (Viagra) and tadalafil (Cialis) may not be suitable candidates for treating dementia.

4 Oct 2022

Nursing home study shows 4th COVID mRNA dose provides extra protection against severe Omicron outcomes

In a recent study posted to the medRxiv* preprint server, researchers in Canada assessed the effectiveness of protection elicited by the fourth dose of the coronavirus disease 2019 (COVID-19) mRNA vaccine.

4 Oct 2022

Study: Lack of naloxone linked to high rates of overdose deaths in rural areas

Pennsylvania has one of the highest rates of opioid overdose in the nation, and, according to Penn State researchers, one's chances of surviving that overdose can depend on where the person lives.

3 Oct 2022

A case for updating COVID vaccines with beta variant spike sequences

A recent Nature Communications study has discussed preclinical and clinical data on COVID-19 vaccine antigens that could be utilized to develop effective booster vaccines.

3 Oct 2022

Seda announces open day

Seda Pharmaceutical Development Services are delighted to announce an Open Day on Tuesday 8th November 2022.

From Seda Pharmaceutical Development Services 3 Oct 2022

Optibrium strengthens global AI drug discovery software operations with three key appointments

Optibrium, a leading developer of software and artificial intelligence (AI) solutions for drug discovery, today announced three key appointments.

From Optibrium Ltd. 3 Oct 2022

Broadly neutralizing antibodies are the blueprint for variant-proof, pansarbecovirus vaccines

A recent Nature Reviews Immunology study has summarized the efficacy of neutralizing antibodies that target four main regions of the spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), namely, the receptor-binding domain (RBD) in the S1 subunit, the fusion peptide region in the S2 subunit, the stem helix region, and the N-terminal domain.

2 Oct 2022

Burt's Bees research shows the benefits of nature-based regimens to protect and restore skin health

Burt's Bees, the #1 dermatologist recommended natural skin care brand and a pioneer in this area, announced its latest research findings on the benefits of nature-based regimens to protect and restore skin health across various skin conditions, types, and tones.

30 Sep 2022

A novel method to identify spike stabilizing mutations for COVID-19 vaccine development

Researchers discuss a robust method to identify mutations that improve the expression and stabilize the conformation of the SARS-CoV-2 spike protein.

29 Sep 2022

First data on Pfizer-BioNTech's Omicron BA.4/5 combination vaccine

In a recent study posted to the bioRxiv* preprint server, researchers from Germany and the United States analyzed the association between exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.4/BA.5 spike glycoprotein and pan-Omicron neutralization.

27 Sep 2022

Review says dose of approved COVID-19 vaccines based on weak evidence

A recent study posted to the medRxiv* preprint server reviewed early-phase dose-finding trials to examine the study design, safety, and early antibody response data on approved coronavirus disease 2019 (COVID-19) vaccines and gain insights on design improvements for future candidate COVID-19 vaccine clinical trials.

26 Sep 2022

Study looks at boosting with variant-derived COVID vaccine

In a recent study posted to bioRxiv*, researchers at Washington University School of Medicine, St. Louis, demonstrated that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine booster elicits robust germinal center (GC) B cell responses.

26 Sep 2022

Designing a new treatment to treat migraine effectively

In this interview, we speak to Mudra Kapoor, Vice President of Global Medical Affairs for Neuroscience at AbbVie, about atogepant, their new treatment option for migraine.

From AbbVie 26 Sep 2022

Study of 9 million Swedes shows rapidly declining effectiveness of COVID vaccines against Omicron

The findings of a new Swedish study posted to the Preprints with The Lancet* server found that two COVID-19 vaccine doses provided effective long-term protection against infection before Omicron, but less protection against Omicron infection (dropping to 43% by week four and no protection by week 14).

25 Sep 2022

Trial tests efficacy and safety of NVX-CoV2373 COVID-19 vaccine among adolescents

In a recent study posted to the medRxiv* preprint server, researchers in the United States described the safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), tested in PREVENT-19 — a phase 3, randomized, placebo-controlled, observer-blinded trial among 12- to 17-year-old adolescents in the United States (U.S).

25 Sep 2022

New engineered peptides could prevent the superbug crisis

A recent study reports the development of a synthetic antibacterial peptide PLG0206.

22 Sep 2022

All SARS-CoV-2 variants blocked by a simple peptide with nanomolar neutralizing efficacy

In a recent study published in the journal PNAS, researchers from Finland and the United States reported a novel heptad repeat 2 (HR2) peptide that inhibited severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) without any chemical modifications.

21 Sep 2022

Healthy people with high cholesterol don't stand to benefit from statins, research says

About 40 million adults in the United States regularly take statins to lower their cholesterol levels and reduce their risk of heart disease and stroke, according to American Heart Association data from 2020.

20 Sep 2022

Molecular engineered low-cost highly effective RBD-based COVID vaccine

In a recent study posted to the bioRxiv* preprint server, an international team of researchers developed a second-generation severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor binding domain (RBD) antigen (RBD-J6) by molecular engineering with two additional amino acid (aa) substitutions (S383D and L518D mutations) in a hydrophobic cryptic RBD core epitope to enhance stability and expression against SARS-CoV-2 variants of concern (VOCs).

19 Sep 2022

Previous
1
...
76
77
78
79
80
81
82
...
1443
Next